DAPHNe: De-escalation to Adjuvant Antibodies Post-pCR to Neoadjuvant THP (Paclitaxel/Trastuzumab/Pertuzumab)-a Pilot Study in HER2-positive Breast Cancer
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
- 试验地点
- 5
- 主要终点
- Adjuvant chemotherapy Received
研究概览
简要总结
This research study is studying whether participants and their doctors are willing to determine post-surgery treatment on the basis of response to pre-surgery treatment, and studying blood and tissue collected from participants treated with a combination of drugs as a treatment for breast cancer.
The names study drugs involved in this study are:
- Paclitaxel (also called Taxol)
- Trastuzumab (also called Herceptin)
- Pertuzumab (also called Perjeta)
详细描述
This research study is a Pilot Study, which means investigators are looking at the feasibility of a new approach for deciding the optimal medical treatment for this type of breast cancer. The FDA (the U.S. Food and Drug Administration) has approved paclitaxel, trastuzumab, and pertuzumab as part of a pre-operative treatment option for this disease.
The purpose of this study is to evaluate whether participants and their doctors are willing to accept a treatment recommendation for post-operative chemotherapy, on the basis of the participant's response to pre-operative treatment with paclitaxel, trastuzumab, and pertuzumab.
In addition, the investigators are evaluating how the body's immune system works with paclitaxel, trastuzumab, and pertuzumab to kill cancer cells. For this reason, the investigators will collect samples of the participant's breast tumor and samples of the participant's blood over time to understand the reaction of the immune system to the participant's tumor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have Stage II or III (according to AJCC cancer staging manual anatomic staging table, 8th edition) histologically confirmed invasive carcinoma of the breast. A minimum tumor size of 1.5 cm determined by physical exam or imaging (whichever is larger) is required. Patients with inflammatory breast carcinoma (T4d) are NOT eligible.
- •Tumors must be HER-2 positive, as assessed by standard local institutional protocol (central testing is not required):
- •FISH positive based on one of the three following criteria:
- •Single-probe average HER2 copy number ≥ 6.0 signals/cell; OR
- •Dual-probe HER2/CEP17 ratio <2.0 with an average HER2 copy number ≥ 6.0 signals/cell; OR
- •Dual-probe HER2/CEP17 ratio ≥2.0
- •ER/PR determination is required. ER- and PR-assays should be performed by immunohistochemical methods according to the local institution standard protocol.
- •Bilateral breast cancers are allowed as long as both cancers are HER2-positive (as defined in 3.1.2), or the contralateral cancer is a <1 cm, ER+, and HER2- tumor.
- •Patients with multifocal or multicentric disease are eligible as long as all tumor foci that were tested for HER2 status at the local institution are HER2-positive, and at least one tumor focus meets eligibility criteria.
- •Breast imaging should include dedicated ultrasound of the ipsilateral axilla. For subjects with a clinically positive axilla based on exam or imaging, a fine needle aspiration or core biopsy procedure will be performed to determine the presence of metastatic disease in the lymph nodes (though lymph node sampling procedure need not be resulted prior to patient's registration on trial, as long as all other eligibility are met).
- •Men and women (with any menopausal status) ≥ 18 years of age are eligible.
- •ECOG PS 0 or
- •Required laboratory values:
- •ANC ≥ 1000/mm3
- •Hemoglobin ≥ 9 g/dl
- •Platelets ≥ 100,000/mm3
- •Serum creatinine < 1.5 x ULN (institutional) OR calculated GFR ≥60mL/min.
- •Total bilirubin ≤ 1.5 x ULN (institutional). For patients with Gilbert Syndrome, the direct bilirubin should be within the institutional normal range OR total bilirubin ≤ 2.0 mg/dL.
- •AST and ALT ≤ 2.5x ULN (institutional)
- •Left ventricular ejection fraction (LVEF) ≥ 50%.
- •Premenopausal women must have a negative serum pregnancy test within 14 days of registration, including women who have had a tubal ligation and for women less than 12 months after the onset of menopause.
- •Women of childbearing potential and men with partners of childbearing potential must be willing to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment and for 7 months after the last dose of study treatment.
- •Patients with a history of ipsilateral DCIS are eligible.
- •Patients undergoing breast conservation therapy (i.e. lumpectomy) must not have any contraindications to radiation therapy.
- •Willing and able to sign informed consent.
- •Willing to provide tissue for research purposes
排除标准
- •Pregnant or nursing women due to the teratogenic potential of the study drugs.
- •Active, unresolved infection.
- •Receipt of intravenous antibiotics for infection within 7 days prior to registration.
- •Uncontrolled hypertension (systolic >180 mm Hg and/or diastolic >100 mm Hg) or clinically significant (i.e. active) cardiovascular disease: cerebrovascular accident/stroke or myocardial infarction within 6 months prior to first study medication, unstable angina, congestive heart failure (CHF) of New York Heart Association (NYHA) Class II or higher (see Appendix B), or serious cardiac arrhythmia requiring medication.
- •Significant symptoms (Grade ≥ 2) from peripheral neuropathy.
- •Other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness, uncontrolled infections, uncontrolled diabetes.
- •Any prior treatment for the current breast cancer, including chemotherapy, hormonal therapy, radiation, or experimental therapy
研究组 & 干预措施
Paclitaxel+Trastuzumab+Pertuzumab
Paclitaxel is administered intravenously on days 1, 8, and 15 of each 21-day cycle Trastuzumab is administered intravenously on day 1 of each 21-day cycle Pertuzumab is administered intravenously on Day 1 of each 21-day cycle
干预措施: Paclitaxel (Drug)
Paclitaxel+Trastuzumab+Pertuzumab
Paclitaxel is administered intravenously on days 1, 8, and 15 of each 21-day cycle Trastuzumab is administered intravenously on day 1 of each 21-day cycle Pertuzumab is administered intravenously on Day 1 of each 21-day cycle
干预措施: Trastuzumab (Drug)
Paclitaxel+Trastuzumab+Pertuzumab
Paclitaxel is administered intravenously on days 1, 8, and 15 of each 21-day cycle Trastuzumab is administered intravenously on day 1 of each 21-day cycle Pertuzumab is administered intravenously on Day 1 of each 21-day cycle
干预措施: Pertuzumab (Drug)
结局指标
主要结局
Adjuvant chemotherapy Received
时间窗: 2.5 years
To assess adherence to protocol-specified antibody doublet therapy in the adjuvant setting among patients with stage II-III HER2+ breast cancer who achieve pathologic complete response (pCR) following neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab (THP).
次要结局
- Overall survival (OS)(12 years)
- Recurrence-Free Interval (RFI)(12 years)
- pCR rate(2 years)
- Residual Cancer Burden (RCB) scores(2 years)
- Reasons for Off-Protocol Escalation per study-specific questionnaires(2 years)
- Reasons for Off-Protocol De-Escalation per study-specific questionnaires(2 years)
- One Year of Trastuzumab and Pertuzumab(3 years)
- Event-Free Survival (EFS)(12 years)
- Post-THP (Paclitaxel/Trastuzumab/Pertuzumab) imaging findings and pathology findings in the surgical specimen(2 years)
研究者
Adrienne G. Waks
Principal Investigator
Dana-Farber Cancer Institute